Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous Close | 14.06 |
| Open | 13.95 |
| Bid | 13.86 x 4000 |
| Ask | 14.00 x 4000 |
| Day's Range | 13.85 - 14.01 |
| 52 Week Range | 13.05 - 17.31 |
| Volume | |
| Avg. Volume | 2,702,567 |
| Market Cap | 43.041B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | 25.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.80 (5.71%) |
| Ex-Dividend Date | Sept 29, 2021 |
| 1y Target Est | N/A |
- Reuters
Takeda, Nintendo among Japanese firms quietly celebrating weak yen
Japan's yen is at its weakest in decades and inflicting high costs of imported food and fuel on households and businesses, but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda. As the Bank of Japan reiterated its commitment to loose monetary policy on Friday, affirming its position as a standalone dove in a global environment of rising inflation, the yen edged back towards the 135.60-per-dollar lows it struck this week. Nearly half of companies that responded to a Tokyo Shoko Research poll this week said the weaker yen would have a negative impact on their businesses.
- Motley Fool
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes
Dividend stocks are just as prone as other stocks to underperforming the market and doing pretty much everything except what you want them to do -- increase and pay out. The catch is that some of the worst dividend investing mistakes are disguised as being juicy opportunities. Let's go over three of the most tempting and most destructive foibles so that you'll be protected against them when you're figuring out which passive income stocks are worth your money.
- Yahoo Finance
FDA advisory committee recommends Novavax vaccine for use in adults
FDA votes to recommend use of Novavax COVID-19 vaccine in adults
